Frank Stegmeier

Q Therapeutics (United States)

Full Professor(heuristic)

CRISPR and Genetic Engineering · Molecular Biology

h-index36

i10-index40

Publications132

Citations16,633

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 15 of 15

Dual-inactivation of Regnase-1 and SOCS1 rewires exhausted CD8 <sup>+</sup> T cell fate to enhance anti-tumor functionality
bioRxiv (Cold Spring Harbor Laboratory) · 2026-01-23 · 3 citations
Data from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient TumorsPreprint
2024-10-15 · 1 citations
Figure S5 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient TumorsPreprint
2024-10-15
Figure S2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient TumorsPreprint
2024-10-15
Figure S3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient TumorsPreprint
2024-10-15
Figure S4 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient TumorsPreprint
2024-10-15
Figure S7 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient TumorsPreprint
2024-10-15
Figure S8 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient TumorsPreprint
2024-10-15
Supplementary Table 1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024-10-15
Figure S9 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient TumorsPreprint
2024-10-15
Supplementary Table 3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024-10-15
Supplementary Table 1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024-10-15
Figure S6 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient TumorsPreprint
2024-10-15
Figure S1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient TumorsPreprint
2024-10-15
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Cancer Research · 2024-08-26 · 48 citations

Open author page on OpenAlex →